Literature DB >> 11967322

Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins.

Pablo Sarobe1, Juan José Lasarte, Noelia Casares, Ascensión López-Díaz de Cerio, Elena Baixeras, Pablo Labarga, Nicolás García, Francisco Borrás-Cuesta, Jesús Prieto.   

Abstract

Patients infected with hepatitis C virus (HCV) have an impaired response against HCV antigens while keeping immune competence for other antigens. We hypothesized that expression of HCV proteins in infected dendritic cells (DC) might impair their antigen-presenting function, leading to a defective anti-HCV T-cell immunity. To test this hypothesis, DC from normal donors were transduced with an adenovirus coding for HCV core and E1 proteins and these cells (DC-CE1) were used to stimulate T lymphocytes. DC-CE1 were poor stimulators of allogeneic reactions and of autologous primary and secondary proliferative responses. Autologous T cells stimulated with DC-CE1 exhibited a pattern of incomplete activation characterized by enhanced CD25 expression but reduced interleukin 2 production. The same pattern of incomplete lymphocyte activation was observed in CD4(+) T cells responding to HCV core in patients with chronic HCV infection. However, CD4(+) response to HCV core was normal in patients who cleared HCV after alpha interferon therapy. Moreover, a normal CD4(+) response to tetanus toxoid was found in both chronic HCV carriers and patients who had eliminated the infection. Our results suggest that expression of HCV structural antigens in infected DC disturbs their antigen-presenting function, leading to incomplete activation of anti-HCV-specific T cells and chronicity of infection. However, presentation of unrelated antigens by noninfected DC would allow normal T-cell immunity to other pathogens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967322      PMCID: PMC136154          DOI: 10.1128/jvi.76.10.5062-5070.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  A cell culture model for T lymphocyte clonal anergy.

Authors:  R H Schwartz
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

2.  Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix.

Authors:  R Fridman; O Lider; Y Naparstek; Z Fuks; I Vlodavsky; I R Cohen
Journal:  J Cell Physiol       Date:  1987-01       Impact factor: 6.384

3.  Inhibition of dendritic cell maturation by herpes simplex virus.

Authors:  M Salio; M Cella; M Suter; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

4.  Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells.

Authors:  L Frasca; P Del Porto; L Tuosto; B Marinari; C Scottà; M Carbonari; A Nicosia; E Piccolella
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

5.  Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.

Authors:  J Engelmayer; M Larsson; M Subklewe; A Chahroudi; W I Cox; R M Steinman; N Bhardwaj
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

6.  The activation of resting lymphocytes is accompanied by the biogenesis of lysosomal organelles.

Authors:  I Olsen; G Bou-Gharios; D Abraham
Journal:  Eur J Immunol       Date:  1990-10       Impact factor: 5.532

7.  Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages.

Authors:  C H Lee; Y H Choi; S H Yang; C W Lee; S J Ha; Y C Sung
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

8.  Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls.

Authors:  Y Castelruiz; E Larrea; P Boya; M P Civeira; J Prieto
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

9.  Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer.

Authors:  N Kato; H Yoshida; S K Ono-Nita; J Kato; T Goto; M Otsuka; K Lan; K Matsushima; Y Shiratori; M Omata
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

10.  Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups.

Authors:  R H Miller; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  35 in total

Review 1.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

2.  Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice.

Authors:  Kilian Weigand; Franziska Voigt; Jens Encke; Birgit Hoyler; Wolfgang Stremmel; Christoph Eisenbach
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

3.  Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment.

Authors:  Yang Hyun Baek; Sung Wook Lee; Hyun Seung Yoo; Hyun Ah Yoon; Ja Won Kim; Young Hoon Kim; Ha Youn Kim; Sang Young Han
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

4.  Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

Authors:  Pablo Sarobe; Juan José Lasarte; Aintzane Zabaleta; Laura Arribillaga; Ainhoa Arina; Ignacio Melero; Francisco Borrás-Cuesta; Jesús Prieto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells.

Authors:  Hua Liang; Rodney S Russell; Nicole L Yonkers; David McDonald; Benigno Rodriguez; Clifford V Harding; Donald D Anthony
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

6.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

Review 7.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

8.  Hepatitis C virus modulates human monocyte-derived dendritic cells.

Authors:  E A Eksioglu; J R Bess; H Zhu; Y Xu; H-J Dong; J Elyar; D R Nelson; C Liu
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

9.  Expression of hepatitis C virus core protein in hepatocytes does not modulate proliferation or apoptosis of CD8+ T cells.

Authors:  Young-Hee Jin; I Nicholas Crispe; Sun Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

10.  Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model.

Authors:  John R Lukens; Michael W Cruise; Matthew G Lassen; Young S Hahn
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.